Maternal plasma phospholipid polyunsaturated fatty acids in pregnancy with and without gestational diabetes mellitus: relations with maternal factors.
BACKGROUND
The fatty acids arachidonic acid (AA; 20:4n-6) and docosahexaenoic acid (DHA; 22:6n-3) are essential for fetal growth and development, but their metabolism may be altered in insulin resistance.


OBJECTIVE
The objectives were to determine maternal plasma phospholipid polyunsaturated fatty acid concentrations in pregnant women receiving dietary therapy for gestational diabetes mellitus (GDM) and to identify maternal factors associated with plasma phospholipid AA and DHA concentrations in the third trimester.


METHODS
Fasting plasma phospholipid fatty acids were determined in women with GDM (n = 15) receiving dietary therapy only and in healthy, pregnant women without GDM (control group, n = 15) at 27-30, 33-35, and 36-39 wk gestation.


RESULTS
Maternal plasma phospholipid (as % by wt of total fatty acids and mg/L) linoleic acid (18:2n-6), AA, and 22:5n-6 concentrations did not differ significantly between women with GDM and control subjects. The other n-6 long-chain polyunsaturated fatty acids (% by wt) were lower in GDM subjects than in control subjects. Plasma phospholipid (expressed as % by wt and mg/L) linolenic acid (18:3n-3) and summed precursors of DHA were lower and DHA (% by wt and mg/L), adjusted for dietary DHA intake, was 13% higher in GDM subjects than in control subjects. Maternal blood hemoglobin A1C was inversely related to plasma phospholipid AA (% by wt) (r = -0.56, P = 0.03) in control subjects and positively associated with plasma phospholipid AA (% by wt) in women with GDM (r = 0.76, P = 0.001). Pregravid body mass index was negatively associated with plasma phospholipid DHA (% by wt) in control subjects (r = -0.55, P = 0.04) and in women with GDM with a body mass index (in kg/m2) <30 (r = -0.76, P = 0.007).


CONCLUSIONS
This is the first report documenting alterations in maternal plasma phospholipid PUFAs in pregnant women receiving dietary therapy for GDM. In pregnant woman, both with and without GDM, maternal glycemic control and pregravid BMI appear to be significant predictors of plasma phospholipid AA and DHA, respectively, during the third trimester. Additionally, dietary DHA significantly affects phospholipid DHA concentrations.
Departments of Nutritional Sciences and Animal Sciences, University of Connecticut, Storrs 06269-4017, USA.
V
V
Wijendran
R B
RB
Bendel
S C
SC
Couch
E H
EH
Philipson
K
K
Thomsen
X
X
Zhang
C J
CJ
Lammi-Keefe
D016718:Arachidonic Acid / Q000008:administration & dosage / Q000097:blood; D015992:Body Mass Index; D016640:Diabetes, Gestational / Q000097:blood* / Q000178:diet therapy*; D004040:Dietary Carbohydrates / Q000008:administration & dosage; D004041:Dietary Fats / Q000008:administration & dosage; D004044:Dietary Proteins / Q000008:administration & dosage; D004281:Docosahexaenoic Acids / Q000097:blood; D002149:Energy Intake; D005231:Fatty Acids, Unsaturated / Q000097:blood*; D005260:Female; D005865:Gestational Age; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D010743:Phospholipids / Q000097:blood*; D011247:Pregnancy
D016718:Arachidonic Acid; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D004044:Dietary Proteins; D004281:Docosahexaenoic Acids; D005231:Fatty Acids, Unsaturated; D006442:Glycated Hemoglobin; D010743:Phospholipids